Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang, M Rule, S Martin, P Goy, A Auer, R Kahl, B Jurczak, W Advani, R Romaguera, J Williams, M
Wang, M
Rule, S
Martin, P
Goy, A
Auer, R
Kahl, B
Jurczak, W
Advani, R
Romaguera, J
Williams, M
Citations
Altmetric:
Abstract
Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.
Authors
Wang, M
Rule, S
Martin, P
Goy, A
Auer, R
Kahl, B
Jurczak, W
Advani, R
Romaguera, J
Williams, M
Barrientos, J
Chmielowska, E
Radford, John A
Stilgenbauer, S
Dreyling, M
Jedrzejczak, W
Johnson, P
Spurgeon, S
Li, L
Zhang, L
Newberry, K
Ou, Z
Cheng, N
Fang, B
McGreivy, J
Clow, F
Buggy, J
Chang, B
Beaupre, D
Kunkel, L
Blum, K
Rule, S
Martin, P
Goy, A
Auer, R
Kahl, B
Jurczak, W
Advani, R
Romaguera, J
Williams, M
Barrientos, J
Chmielowska, E
Radford, John A
Stilgenbauer, S
Dreyling, M
Jedrzejczak, W
Johnson, P
Spurgeon, S
Li, L
Zhang, L
Newberry, K
Ou, Z
Cheng, N
Fang, B
McGreivy, J
Clow, F
Buggy, J
Chang, B
Beaupre, D
Kunkel, L
Blum, K
Description
Date
2013-08-08
Publisher
Collections
Keywords
Type
Article
Citation
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. 2013, 369 (6):507-16 N Engl J Med